You are here
Enrollment in Clinical Studies for Angiogenic Gene Therapy Candidate Stopped
The company’s analysis of the interim data of one of the studies has led it to conclude that the studies, as currently designed, will not provide sufficient evidence of efficacy to warrant continued enrollment. The company is instructing investigators to stop patient enrollment. All patients who have already been treated will continue to be evaluated.
Each study is being monitored by an independent Data Safety Monitoring Board (DSMB). No evidence of important safety concerns was found.
Schering AG continues to evaluate and explore the potential of this highly innovative technology.
Source: Schering AG